Back to drug list

Avsola (infliximab-axxq)


Billing

Code: Q5121

Description: Inj. avsola, 10 mg

Unit: 10 mg

Payment: $28.334

Pay quarter: Q3 2023


Medicare history

Dosage and Frequency

Crohn's Disease (CD)
Ulcerative Colitis (UC)
Ankylosing Spondylitis (AS)
Psoriatic Arthritis (PsA)
Plaque Psoriasis (Ps)

Induction:
• 5mg/kg IV at 0, 2, and 6 weeks

Maintenance:
• 5mg/kg IV every 8 weeks

Rheumatoid Arthritis (RA)

Induction:
• 3mg/kg IV at 0, 2, and 6 weeks

Maintenance:
• 3mg/kg IV every 8 weeks

Calculate drug reimbursement


Total Reimbursement:

$901.02

(ASP: $850.02, Margin: $51.00)


Code:

Q5121

# Units to bill:

30

Prior Authorization

Prior auth criteria for Avsola may include but is not limited to:


1. Patients must meet the criteria for a diagnosis of a chronic condition as listed in the Avsola product labeling.

2. Patients must have tried and failed, or have an contraindication to, an appropriate alternative therapy.

3. Patients must have a medically appropriate and documented response to a trial of therapy with Avsola.

4. The treatment plan must be medically necessary and appropriate for the patient’s condition.

5. The patient’s medical record must include documentation of the patient’s response to the trial of Avsola and other treatment regimens.

6. The patient must be 18 years of age or older.

7. The prescribing physician must be a board-certified or board-eligible physician in the United States with a valid, unrestricted license.

8. The prescribing physician must have adequate experience and knowledge of the patient’s condition to make an informed judgment about the potential risks and benefits of prescribing Avsola for the patient.


Insurance prior auth guidelines:

Aetna

United Healthcare

Anthem

Cigna


Billable NDCs

55513-0670-01

Avsola (AMGEN USA, INC.)

100 MG



Resources

Drug Enrollment Form

Website